Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial

The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with multiple HER2-expressing advanced solid tumours. These positive outcomes mark the successful achievement of two secondary endpoints of the trial.

In the primary analysis, Enhertu demonstrated durable responses, as assessed by the investigator-confirmed objective response rate (ORR) – the trial’s primary endpoint, and duration of response (DoR) – another secondary endpoint. These findings corroborate the results of an interim analysis of the trial, recently presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Enhertu is a HER2-directed antibody drug conjugate (ADC) developed and commercialised by AstraZeneca and Daiichi Sankyo.

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, stated: “The progression-free survival and overall survival results for Enhertu underscore the potential value of this important medicine for patients with HER2-expressing cancers who currently have no targeted treatment options. We are working with health authorities to bring Enhertu to patients with HER2-expressing cancers that could potentially benefit from this medicine as quickly as possible.”

Mark Rutstein, Global Head, Oncology Development at Daiichi Sankyo, expressed: “These updated results from the DESTINY-PanTumor02 trial are important as we work to reshape the clinical landscape in HER2-expressing advanced cancers. The overall survival demonstrated by Enhertu in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with HER2-expressing cancers.”

The Phase II trial has been investigating the efficacy and safety of Enhertu in patients with previously treated locally advanced, unresectable, or metastatic HER2-expressing solid tumours not eligible for curative therapy. The safety profile observed in the primary analysis remains consistent with previous data and other trials of Enhertu, with no new safety concerns identified.